Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in healthy male volunteers
NCT02525679Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in generalized pustular psoriasis (GPP) comparing Spesolimab with Placebo (2 arms). Primary endpoint: Percentage of Subjects With Drug Related Adverse Events at 74 days. Started Sep 2015; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT02525679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525679.